CMS has launched the BALANCE Model, a five-year test to lower costs & expand Medicare access to GLP-1 weight-loss drugs while ...

NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with ...

Dec 23 (Reuters) - The U.S. Centers for Medicare and Medicaid Services on Tuesday unveiled a voluntary program to cover GLP-1 drugs for weight-loss and diabetes under Medicaid and Medicare Part D ...

In recent days, Amazon Pharmacy announced it would begin offering Novo Nordisk’s Wegovy once-daily weight-loss pill through ...